RxDoctor Payments DataLook up a doctor →

Kristen Bevill, MD

Psychiatry · Jackson, MSNPI 1841315546

Payments from drug & device makers

$11,508in general payments, 2019–2025

Across 709 payments — averaging $16.23 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • Lundbeck LLC$2K
  • Takeda Pharmaceuticals U.S.A., Inc.$1K
  • Johnson & Johnson$834
  • Vanda Pharmaceuticals Inc.$789
  • Otsuka America Pharmaceutical, Inc.$784
  • plus $4K from 26 others

What the payments were for

  • Food & beverage$11,26498%
  • Education$2442%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$11,508 in reported general payments places this provider in the 90th percentile of 219 psychiatry providers in Mississippi.

See all psychiatry providers in Mississippi

Medicare billing

Part B allowed, 2024
$64,226
Medicare patients
113
Services billed
741

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Austedo XrDeutetrabenazine15$84,366
RexultiBrexpiprazole19$28,787
VraylarCariprazine Hcl14$22,746
Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl79$14,621
TrintellixVortioxetine Hydrobromide20$9,001
QuviviqDaridorexant Hcl12$5,950
Clomipramine Hcl20$2,611
Bupropion XlBupropion Hcl168$2,262
Desvenlafaxine Succinate ErDesvenlafaxine Succinate43$1,929
Duloxetine Hcl97$1,927
Fluvoxamine Maleate46$1,702
Quetiapine Fumarate70$1,485
Buspirone Hcl76$1,078
Carbamazepine23$1,002
Naltrexone Hcl23$923

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Teva Pharmaceuticals USA, Inc.Austedo Xr$754$84,36615 claims
Otsuka America Pharmaceutical, Inc.Rexulti$784$28,78719 claims
AbbVieVraylar$2,330$22,74614 claims
Takeda Pharmaceuticals U.S.A., Inc.Trintellix$1,305$9,00120 claims
Idorsia Pharmaceuticals US IncQuviviq$45$5,95012 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 219 psychiatry providers in Mississippi.

Other psychiatry in Jackson

See the full list for Mississippi

Where these figures come from

Is this you, or does something look wrong? →